Single-cell gene expression links SARS-CoV-2 infection and gut serotonin

We read with great interest the paper by Ha et al demonstrating that circulating levels of serotonin (5-hydroxytryptamine, 5-HT) are increased in COVID-19 and correlate with disease severity and gastrointestinal symptoms such as diarrhoea. Another recent paper by Lin et al demonstrated that diarrhoea is the most common GI symptom in patients with COVID-19. Almost all 5-HT in our body is produced by enterochromaffin (EC) cells within the epithelium of the GI tract, which constitute approximately half of all enteroendocrine (EE) cells. Gut-derived 5-HT modulates gut peristalsis and exacerbates inflammatory responses by acting as a chemotactic molecule for various immune cells and by triggering cytokine release. While most gut epithelial cell types are susceptible to SARS-CoV-2 infection, EE cells have the greatest proportion of cells infected at 12 hours after viral exposure. In addition, the use of selective serotonin reuptake inhibitors (SSRI), normally prescribed to treat mental health conditions such as depression, is reported to reduce COVID-19 severity in humans. However, its unknown if EC cells have any specific capacity for infection that would explain the increased 5-HT in patients with COVID-19, or the SSRI treatment efficacy reported. We, therefore, examined (see online supplemental file 1) the transcriptomes of cells lining the gut wall for expression of genes associated with SARS-CoV-2 infection, with a focus on EE cell subtypes.

Our focus was on gene expression for proteins implicated or known to be involved as COVID-19 receptors for efficient cell entry; ACE2, BSG and NRP1, associated proteins involved in intracellular trafficking and breakdown; TMPRSS2, FURIN and CTSD, and proteins associated with viral protection; LY6E, IFITM1-3 and IFNAR1-2. We identified that the genes encoding for all of these proteins are expressed within the intestinal epithelium (figure 1). Of the known COVID-19 receptors, Ace2 and Bsg genes are highly expressed in all epithelial cell types. However, the more recently identified receptor, NRP1, is expressed exclusively in hormone-producing EE cells at the gene level.

To examine this further, we determined which subtypes of EE cells express Nrp1 (figure 2). We focused on the major EE cell types containing cholecystokinin, glucagon-like peptide-1, ghrelin, neurotensin, somatostatin and 5-HT (figure 2A). EC cells that express tryptophan hydroxylase 1 (Tph1), the rate-limiting enzyme for non-neuronal 5-HT synthesis, are the primary cell type in the gut wall expressing Nrp1, indicating these cells may be a route of infection and disease pathogenesis. We then focused solely on EE cell gene expression using a second RNA-seq database and found that while all COVID-19-related genes are expressed in EC cells, Nrp1 has the greatest enrichment of expression of all these, of approximately 45-fold greater expression in EC cells than in non-EC epithelial cells (figure 2B). Subsequent examination of published work identifies that NRP1 protein expression is highly colocalised in the gastrointestinal wall with cells that express chromogranin-A, a marker of EC cells.

Cells expressing NRP1, ACE2 and TMPRSS2 have a >3-fold increase in SARS-CoV-2 infection compared with ACE2 and TMPRSS2 alone. Our data demonstrate that EC cells are the only gut cell type that expresses significant levels of these three SARS-CoV-2-related genes. This, therefore, provides a link between...
EC cells and the increased diarrhoea,

circulating 5-HT, and efficacy of SSRIs that are reported in COVID-19. Experiments investigating SARS-CoV-2 infectivity in the absence of gut-derived 5-HT would provide further evidence of this link.

Alyce M Martin, Michael Roach, Lauren A Jones, Daniel Thorpe, Rosemary A Coleman, Caitlin Allman, Robert Edwards, Damien J Keating

Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia

Flinders Accelerator for Microbiome Exploration, College of Science and Engineering, Flinders University, Adelaide, South Australia, Australia

Correspondence to Professor Damien J Keating, Flinders Health and Medical Research Institute and College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia

Twitter Alyce M Martin @alyce_martin and Lauren A Jones @ConfocalJones

Contributors AMM, LAJ and DJK developed the concept; MR and RE performed bioinformatic analysis; MR and AMM made the figures; AMM, LAJ, DT, RAC, CA and DJK edited the literature and wrote the drafts; all authors read and approved the final manuscript for submission.

Funding Supported by grants from the Australian Research Council (DE220100403 to AMM).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; internally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation or adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on non-commercial terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/gutjnl-2022-328262).

To cite Martin AM, Roach M, Jones LA, et al. Gut ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2022-328262

Received 11 July 2022 Accepted 12 August 2022

Gut 2022;0:1–2. doi:10.1136/gutjnl-2022-328262

ORCID iDs Alyce M Martin http://orcid.org/0000-0003-1631-8307 Damien J Keating http://orcid.org/0000-0002-0154-8305

REFERENCES


